Mitchell Gail and Robert Hoover Named NIH Distinguished Investigators
, by DCEG Staff
Mitchell H. Gail, M.D., Ph.D., and Robert N. Hoover, M.D., D.Sc., both tenured senior investigators in DCEG, have been named NIH Distinguished Investigators in recognition of their career achievements and impact on their respective scientific fields.
Dr. Gail has made invaluable contributions to epidemiology and cancer prevention with his expertise in statistical modelling. Most notably, he developed the NCI Breast Cancer Risk Assessment Tool, the first model to estimate a woman's risk of developing invasive breast cancer over the next 5 years and up to age 90 (lifetime risk).
Dr. Hoover, Director of the Epidemiology and Biostatistics Program, has established ongoing programs of research in various areas of cancer epidemiology. His special focus has been in hormonal carcinogenesis, including a long-term follow-up study of diethylstilbestrol (DES)-exposed and -unexposed mothers, daughters and sons, and granddaughters for adverse health effects resulting from this exposure.
NIH Distinguished Investigators are tenured intramural senior investigators who have made outstanding scientific contributions that have had a significant impact in their scientific field, as evidenced by election to highly selective, prestigious professional organizations, publications that have had a significant impact in their scientific field, extraordinary service to the NIH or scientific community, and a record of outstanding achievement in fostering diversity with the NIH scientific workforce and the broader scientific community.
“We are greatly indebted to Dr. Gail and Dr. Hoover for their tireless efforts to deepen our understanding of cancer etiology and improve cancer prevention,” said Stephen J. Chanock, M.D., Division Director. “This honor recognizes the lasting impact of their work.”